Abnormality detection and intelligent severity assessment of human chest computed tomography scans using deep learning: a case study on SARS-COV-2 assessment.

阅读:7
作者:Ibrahim Mohamed Ramzy, Youssef Sherin M, Fathalla Karma M
Different respiratory infections cause abnormal symptoms in lung parenchyma that show in chest computed tomography. Since December 2019, the SARS-COV-2 virus, which is the causative agent of COVID-19, has invaded the world causing high numbers of infections and deaths. The infection with SARS-COV-2 virus shows an abnormality in lung parenchyma that can be effectively detected using Computed Tomography (CT) imaging. In this paper, a novel computer aided framework (COV-CAF) is proposed for classifying the severity degree of the infection from 3D Chest Volumes. COV-CAF fuses traditional and deep learning approaches. The proposed COV-CAF consists of two phases: the preparatory phase and the feature analysis and classification phase. The preparatory phase handles 3D-CT volumes and presents an effective cut choice strategy for choosing informative CT slices. The feature analysis and classification phase incorporate fuzzy clustering for automatic Region of Interest (RoI) segmentation and feature fusion. In feature fusion, automatic features are extracted from a newly introduced Convolution Neural Network (Norm-VGG16) and are fused with spatial hand-crafted features extracted from segmented RoI. Experiments are conducted on MosMedData: Chest CT Scans with COVID-19 Related Findings with COVID-19 severity classes and SARS-COV-2 CT-Scan benchmark datasets. The proposed COV-CAF achieved remarkable results on both datasets. On MosMedData dataset, it achieved an overall accuracy of 97.76% and average sensitivity of 96.73%, while on SARS-COV-2 CT-Scan dataset it achieves an overall accuracy and sensitivity 97.59% and 98.41% respectively.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。